Tscan Therapeutics, Inc. · NASDAQ:TCRX
BVF PARTNERS L P/IL reported a 9.99% stake in Tscan Therapeutics, Inc. (Schedule 13G/A)
Event Jun 30, 2026 · Filed Aug 14, 2026
BVF PARTNERS L P/IL reported a 9.99% stake in Tscan Therapeutics, Inc., 6,417,831 shares, as a passive investor on Jun 30, 2026. Filed Aug 14, 2026 (Schedule 13G/A).
- Stake
- 9.99%
- Shares
- 6,417,831
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 10 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 5.70% | 3,649,002 |
| BVF I GP LLC | 5.70% | 3,649,002 |
| BIOTECHNOLOGY VALUE FUND II LP | 4.20% | 2,662,237 |
| BVF II GP LLC | 4.20% | 2,662,237 |
| Biotechnology Value Trading Fund OS LP | 0.10% | 83,135 |
| BVF Partners OS Ltd. | 0.10% | 83,135 |
| BVF GP HOLDINGS LLC | 9.80% | 6,311,239 |
| BVF PARTNERS L P/IL | 9.99% | 6,417,831 |
| BVF INC/IL | 9.99% | 6,417,831 |
| LAMPERT MARK N | 9.99% | 6,417,831 |
Source
Related
- Tscan Therapeutics, Inc.
- Bvf Partners L P
- Tscan Therapeutics, Inc. shareholders
- Schedule 13G/A · Bvf Partners L P · May 15, 2026
- Schedule 13G/A · Bvf Partners L P · May 15, 2025
- Form 4 · MacBeath Gavin · Oct 2, 2026
- Form 4 · Zdraveski Zoran · Oct 2, 2026
- Schedule 13G · Readout Capital, LP · Sep 25, 2026
- Schedule 13G/A · Lynx1 Capital Management LP · Aug 14, 2026
- Schedule 13G/A · Lynx1 Capital Management LP · Aug 14, 2025